PATENT CLAIM ANALYSIS

Application Number: 16132150
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-05
Patent Classification: ["424", "133100"]

Abstract:
The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering an anti-CTGF antibody. In particular, the treatment methods provided avoid toxicities associated with approved therapies and also avoid the attenuation of the efficacy of an anti-CTGF antibody caused by these approved therapies.

Claim (Index 8):
The method of  claim 6  or  7 , wherein the pulmonary function parameter is selected from the group consisting of vital capacity (VC), residual volume (RV), forced expiratory volume (FEV), forced vital capacity (FVC), forced vital capacity percent predicted (FVCPP), forced expiratory flow (FEF), peak expiratory flow rate (PEFR), inspiratory reserve volume (IRV), functional residual capacity (FRC), inspiratory capacity (IC), total lung capacity (TLC), expiratory reserve volume (ERV), tidal volume (TV), and maximum voluntary ventilation (MVV).

Metadata:
- Claim Count in Document: 8.0
- Percentile: 97.0
- Lexical Diversity: 1.31707
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16028235', '15263767', '14398380', '14741747', '15852977']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8160172107112009
- 35 USC 102 Novelty (BERT): 0.5494015359028845
- Combined Prediction Score: 0.7893556432303693
- Mean Citation Score: 388.63126
- Max Citation Score: 469.31403
- Similarity Product: 275.51226563522283

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test